Company Overview: AZN

AZN Overview

Upcoming Projects (AZN)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (AZN)

A Third Look: Checking in on the prescription trends of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease
Tickers: AZN, SNY
Executed On: Nov 06, 2024 at 04:30 PM EST
A Second Look: Discussing the approval and use of neoadjuvant/adjuvant durvalumab (Imfinzi) for resectable non-small cell lung cancer.
Ticker: AZN
Executed On: Nov 05, 2024 at 02:00 PM EST
Discussing the approval and use of neoadjuvant/adjuvant durvalumab (Imfinzi) for resectable non-small cell lung cancer.
Ticker: AZN
Executed On: Nov 04, 2024 at 05:00 PM EST
A Second Look: Checking in on the prescription trends of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease
Tickers: AZN, SNY
Executed On: Nov 04, 2024 at 01:00 PM EST
Checking in on the prescription trends of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease
Tickers: AZN, SNY
Executed On: Oct 30, 2024 at 11:30 AM EDT
A Third look: Perusing the phase 3 AMPLIFY clinical trial data of Calquence in patients with CLL
Ticker: AZN
Executed On: Oct 30, 2024 at 10:00 AM EDT
A Third View: Understanding the data behind the newly FDA approved treatment by AstraZeneca - FASENRA® (benralizumab) ,in patients with Eosinophilic granulomatosis with polyangiitis (EGPA)
Ticker: AZN
Executed On: Oct 29, 2024 at 03:30 PM EDT
A Second View: Understanding the data behind the newly FDA approved treatment by AstraZeneca - FASENRA® (benralizumab) ,in patients with Eosinophilic granulomatosis with polyangiitis (EGPA)
Ticker: AZN
Executed On: Oct 25, 2024 at 11:30 AM EDT
A Third Opinion: Discussing the FDA Approval of AstraZeneca’s FluMist Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration in patients age 2-49
Ticker: AZN
Executed On: Oct 24, 2024 at 05:30 PM EDT
Understanding the data behind the newly FDA approved treatment by AstraZeneca - FASENRA® (benralizumab) ,in patients with Eosinophilic granulomatosis with polyangiitis (EGPA)
Ticker: AZN
Executed On: Oct 18, 2024 at 02:00 PM EDT
A Second Opinion: Discussing the FDA Approval of AstraZeneca’s FluMist Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration in patients age 2-49
Ticker: AZN
Executed On: Oct 18, 2024 at 01:30 PM EDT
Discussing the FDA Approval of AstraZeneca’s FluMist Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration in patients age 2-49
Ticker: AZN
Executed On: Oct 17, 2024 at 11:00 AM EDT
A Second look: Perusing the phase 3 AMPLIFY clinical trial data of Calquence in patients with CLL
Ticker: AZN
Executed On: Oct 16, 2024 at 09:00 AM EDT
Perusing the phase 3 AMPLIFY clinical trial data of Calquence in patients with CLL
Ticker: AZN
Executed On: Oct 15, 2024 at 11:30 AM EDT
Discussing the current landscape of the seasonal flu, COVID-19, and various vaccinations.
Tickers: GSK, SNY, AZN
Executed On: Oct 01, 2024 at 10:00 AM EDT
A Third Perspective: Checking in with a prescriber of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease.
Tickers: AZN, SNY
Executed On: Sep 11, 2024 at 01:00 PM EDT
A Second Perspective: Checking in with a prescriber of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease.
Tickers: AZN, SNY
Executed On: Sep 06, 2024 at 01:30 PM EDT
Checking in with a prescriber of Beyfortus (nirsevimab) for newborns and infants to prevent RSV-related lower respiratory tract disease.
Tickers: AZN, SNY
Executed On: Aug 26, 2024 at 01:00 PM EDT
A Third Look: Discussing the potential of AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) for patients with moderate to very severe COPD and the results from the Phase IIa COURSE trial presented in May at ATS conference.
Tickers: AMGN, AZN
Executed On: Jul 23, 2024 at 04:30 PM EDT
A Second Look: Discussing the potential of AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) for patients with moderate to very severe COPD and the results from the Phase IIa COURSE trial presented in May at ATS conference.
Tickers: AZN, AMGN
Executed On: Jul 22, 2024 at 11:00 AM EDT
Discussing the potential of AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) for patients with moderate to very severe COPD and the results from the Phase IIa COURSE trial presented in May at ATS conference.
Tickers: AMGN, AZN
Executed On: Jul 15, 2024 at 04:00 PM EDT
A Third Look: Discussing the standard of care for lymphoma and the data on Astrazeneca's BTK inhibitor, Calquence
Ticker: AZN
Executed On: Jul 15, 2024 at 08:30 AM EDT
A Second Look: Discussing the standard of care for lymphoma and the data on Astrazeneca's BTK inhibitor, Calquence
Ticker: AZN
Executed On: Jul 03, 2024 at 01:00 PM EDT
Discussing the standard of care for lymphoma and the data on Astrazeneca's BTK inhibitor, Calquence
Ticker: AZN
Executed On: Jun 28, 2024 at 03:30 PM EDT
A Second Look: Discussing SUPERNOVA Phase III trial of sipavibart long-acting antibody which met primary endpoints in preventing COVID-19 in immunocompromised patient population.
Ticker: AZN
Executed On: Jun 14, 2024 at 12:00 PM EDT
Discussing SUPERNOVA Phase III trial of sipavibart long-acting antibody which met primary endpoints in preventing COVID-19 in immunocompromised patient population.
Ticker: AZN
Executed On: Jun 14, 2024 at 08:45 AM EDT
A Third Look: Discussing the potential of CAR-T applications in immunology and autoimmune diseases.
Tickers: AZN, KYTX, CABA, NKTX, GRCL, Artiva Biotherapeutics
Executed On: May 30, 2024 at 04:30 PM EDT
A Second Look: Discussing the potential of CAR-T applications in immunology and autoimmune diseases.
Tickers: AZN, KYTX, CABA, NKTX, GRCL, Artiva Biotherapeutics
Executed On: May 24, 2024 at 09:00 AM EDT
Discussing the potential of CAR-T applications in immunology and autoimmune diseases.
Tickers: KYTX, CABA, NKTX, GRCL, AZN, Artiva Biotherapeutics
Executed On: May 23, 2024 at 11:00 AM EDT
A Third Look: Discussing the standard of care and potential of AstraZeneca’s FASENRA (benralizumab) which is now FDA approved for patients with severe asthma aged 6 to 11
Ticker: AZN
Executed On: May 22, 2024 at 10:00 AM EDT
A Third Prescriber Check-in on AstraZeneca's Truqap (capivasertib) for patients with breast cancer.
Ticker: AZN
Executed On: May 17, 2024 at 03:30 PM EDT
A Second Opinion: Reviewing the approval of Voydeya (danicopan) in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH
Ticker: AZN
Executed On: May 16, 2024 at 08:30 AM EDT
Reviewing the approval of Voydeya (danicopan) in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH
Ticker: AZN
Executed On: May 02, 2024 at 04:45 PM EDT
A Second Prescriber Check-in on AstraZeneca's Truqap (capivasertib) for patients with breast cancer.
Ticker: AZN
Executed On: Apr 23, 2024 at 07:35 PM EDT
A Second Look: Discussing the standard of care and potential of AstraZeneca’s FASENRA (benralizumab) which is now FDA approved for patients with severe asthma aged 6 to 11
Ticker: AZN
Executed On: Apr 22, 2024 at 10:00 AM EDT
Discussing the standard of care and potential of AstraZeneca’s FASENRA (benralizumab) which is now FDA approved for patients with severe asthma aged 6 to 11
Ticker: AZN
Executed On: Apr 19, 2024 at 12:00 PM EDT
Prescriber Check-in on AstraZeneca's Truqap (capivasertib) for patients with breast cancer.
Ticker: AZN
Executed On: Apr 17, 2024 at 05:00 PM EDT
A Third Look: Discussing the potential of first-in-class PARP1 inhibitor, saruparib, in solid tumors and the results from the phase 1/2a PETRA study presented during the 2024 AACR Annual Meeting.
Ticker: AZN
Executed On: Apr 16, 2024 at 10:00 AM EDT
A Second Look: Discussing the potential of first-in-class PARP1 inhibitor, saruparib, in solid tumors and the results from the phase 1/2a PETRA study presented during the 2024 AACR Annual Meeting.
Ticker: AZN
Executed On: Apr 12, 2024 at 11:00 AM EDT
Discussing the potential of first-in-class PARP1 inhibitor, saruparib, in solid tumors and the results from the phase 1/2a PETRA study presented during the 2024 AACR Annual Meeting.
Ticker: AZN
Executed On: Apr 11, 2024 at 03:15 PM EDT
Discussing the potential of AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy as an FDA approved option.
Tickers: AZN, IONS
Executed On: Mar 26, 2024 at 02:00 PM EDT
A Third Look: Discussing the current treatment landscape for systemic lupus erythematosus and the use of Saphnelo (anifrolumab).
Ticker: AZN
Executed On: Feb 01, 2024 at 01:00 PM EST
A Second Look: Discussing the current treatment landscape for systemic lupus erythematosus and the use of Saphnelo (anifrolumab).
Ticker: AZN
Executed On: Jan 30, 2024 at 12:00 PM EST
Discussing the current treatment landscape for systemic lupus erythematosus and the use of Saphnelo (anifrolumab).
Ticker: AZN
Executed On: Jan 26, 2024 at 09:00 AM EST
A Third Look: Discussing Icosavax's Interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults
Tickers: AZN, ICVX
Executed On: Dec 22, 2023 at 08:00 AM EST
A Second Look: Discussing Icosavax's Interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults
Tickers: AZN, ICVX
Executed On: Dec 19, 2023 at 12:00 PM EST
Discussing Icosavax's Interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults
Tickers: AZN, ICVX
Executed On: Dec 19, 2023 at 08:00 AM EST
Discussing the results from the Phase IIb ZENITH-CKD trial and the potential of zibotentan/dapagliflozin combination for reducing urinary albumin-to-creatinine ratio (UACR) in patients with CKD and proteinuria.
Ticker: AZN
Executed On: Dec 06, 2023 at 04:00 PM EST
Investigating the TROPION-Breast01 phase 3 clinical trial data on datopotamab deruxtecan as a treatment for breast cancer.
Tickers: AZN, DSKYF
Executed On: Nov 29, 2023 at 11:30 AM EST
A Third Look: Discussing the potential of AstraZeneca's take home flu mist vaccine
Ticker: AZN
Executed On: Nov 03, 2023 at 12:00 PM EDT
A Second Look: Discussing the potential of AstraZeneca's take home flu mist vaccine
Ticker: AZN
Executed On: Nov 02, 2023 at 03:00 PM EDT
Discussing the potential of AstraZeneca's take home flu mist vaccine
Ticker: AZN
Executed On: Oct 31, 2023 at 04:30 PM EDT
A Second Look: Delving into the phase 3 clinical trial data on AstraZeneca's TROP2-directed antibody drug conjugate datopotamab deruxtecan.
Ticker: AZN
Executed On: Sep 22, 2023 at 06:00 PM EDT
A Second Look: Discussing the potential of immunotherapy, durvalumab, plus PARP inhibitor, olaparib, as maintenance therapy following platinum-based chemotherapy in patients with endometrial cancer.
Ticker: AZN
Executed On: Sep 14, 2023 at 03:00 PM EDT
Delving into the phase 3 clinical trial data on AstraZeneca's TROP2-directed antibody drug conjugate datopotamab deruxtecan.
Ticker: AZN
Executed On: Aug 18, 2023 at 09:00 AM EDT
Discussing the potential of immunotherapy, durvalumab, plus PARP inhibitor, olaparib, as maintenance therapy following platinum-based chemotherapy in patients with endometrial cancer.
Ticker: AZN
Executed On: Aug 11, 2023 at 11:30 AM EDT
A Third Opinion: Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatrician
Tickers: SNY, AZN
Executed On: Aug 01, 2023 at 09:00 AM EDT
A Second Opinion: Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatric Emergency Room Physician
Tickers: SNY, AZN
Executed On: Jul 20, 2023 at 02:00 PM EDT
Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatric Emergency Room Physician
Tickers: SNY, AZN
Executed On: Jul 19, 2023 at 12:00 PM EDT
A Third View: Examining the treatment landscape and the potential of AstaZeneca's nirsevimab in light of the recent unanimous recommendation by the FDA advisory committee for prevention of RSV lower respiratory tract disease in infants.
Ticker: AZN
Executed On: Jul 11, 2023 at 11:30 AM EDT
A Second View: Examining the treatment landscape and the potential of AstaZeneca's nirsevimab in light of the recent unanimous recommendation by the FDA advisory committee for prevention of RSV lower respiratory tract disease in infants.
Ticker: AZN
Executed On: Jul 10, 2023 at 01:15 PM EDT
Examining the treatment landscape and the potential of AstaZeneca's nirsevimab in light of the recent unanimous recommendation by the FDA advisory committee for prevention of RSV lower respiratory tract disease in infants.
Ticker: AZN
Executed On: Jul 06, 2023 at 10:00 AM EDT
A third look: Discussing the potential of Capivasertib in hormone receptor–positive advanced breast cancer and the Phase 3 data.
Ticker: AZN
Executed On: Jul 05, 2023 at 10:30 AM EDT
A second look: Discussing the potential of Capivasertib in hormone receptor–positive advanced breast cancer and the Phase 3 data.
Ticker: AZN
Executed On: Jun 29, 2023 at 04:30 PM EDT
Discussing the potential of Capivasertib in hormone receptor–positive advanced breast cancer and the Phase 3 data.
Ticker: AZN
Executed On: Jun 28, 2023 at 10:00 AM EDT
A Second Look: Discussing the potential of danicopan, a first-in-class oral Factor D inhibitor, as an add-on to C5 inhibitor therapy in patients with paroxysmal nocturnal haemoglobinuria who experience extravascular haemolysis.
Ticker: AZN
Executed On: Jun 26, 2023 at 05:00 PM EDT
Discussing the potential of danicopan, a first-in-class oral Factor D inhibitor, as an add-on to C5 inhibitor therapy in patients with paroxysmal nocturnal haemoglobinuria who experience extravascular haemolysis.
Ticker: AZN
Executed On: Jun 26, 2023 at 12:00 PM EDT
A Second Opinion: Discussing AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) DESTINY-PanTumor02 Phase II trial and DESTINY-CRC02 Phase II trial data from ASCO 2023 in patients with HER2-expressing advanced solid tumors.
Tickers: AZN, DSKYF
Executed On: Jun 16, 2023 at 05:00 PM EDT
Discussing AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) DESTINY-PanTumor02 Phase II trial and DESTINY-CRC02 Phase II trial data from ASCO 2023 in patients with HER2-expressing advanced solid tumors.
Tickers: AZN, DSKYF
Executed On: Jun 07, 2023 at 03:45 PM EDT
A third opinion: Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: Jun 06, 2023 at 04:30 PM EDT
Discussing the standard of care for prostate cancer and the recent approval of Lynparza for metastatic castration-resistant prostate cancer (mCRPC).
Tickers: AZN, MRK
Executed On: May 30, 2023 at 02:30 PM EDT
A third opinion: Discussing the standard of care and potential of AstraZeneca’s Farxiga (dapagliflozin), which recently received FDA approval of label expansion to treat heart failure in a broader range of patients.
Ticker: AZN
Executed On: May 19, 2023 at 11:00 AM EDT
A second opinion: Discussing the standard of care and potential of AstraZeneca’s Farxiga (dapagliflozin), which recently received FDA approval of label expansion to treat heart failure in a broader range of patients.
Ticker: AZN
Executed On: May 18, 2023 at 07:00 PM EDT
Discussing the standard of care and potential of AstraZeneca’s Farxiga (dapagliflozin), an oral once-daily SGLT2 inhibitor, which recently received FDA approval of label expansion to treat heart failure in a broader range of patients.
Ticker: AZN
Executed On: May 17, 2023 at 12:00 PM EDT
A second opinion: Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: May 11, 2023 at 01:00 PM EDT
Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: May 10, 2023 at 06:15 PM EDT
A second look: Discussing recent advancements and use of synthetic lethality based cancer therapeutics and areas for future development.
Tickers: IDYA, MRK, AZN
Executed On: Mar 21, 2023 at 01:00 PM EDT
Discussing recent advancements and use of synthetic lethality based cancer therapeutics and areas for future development.
Tickers: IDYA, AZN, MRK
Executed On: Mar 16, 2023 at 04:30 PM EDT
A third discussion of the potential of Astra Zeneca and Daiichi Sankyo’s antibody-drug conjugate Datopotamab deruxtecan for non-small cell lung cancer and breast cancer.
Tickers: AZN, DSKYF
Executed On: Feb 27, 2023 at 04:00 PM EST
A second discussion of the potential of Astra Zeneca and Daiichi Sankyo’s antibody-drug conjugate Datopotamab deruxtecan for non-small cell lung cancer and breast cancer.
Tickers: AZN, DSKYF
Executed On: Feb 21, 2023 at 10:00 AM EST
Discussing the potential of Astra Zeneca and Daiichi Sankyo’s antibody-drug conjugate Datopotamab deruxtecan for non-small cell lung cancer and breast cancer.
Tickers: AZN, DSKYF
Executed On: Feb 14, 2023 at 03:00 PM EST
A second review of the recent FDA approval of AstraZeneca's Airsupra (albuterol/budesonide) the first and only rescue medication to reduce risk of asthma exacerbations in adults.
Ticker: AZN
Executed On: Feb 01, 2023 at 12:00 PM EST
Understanding the recent FDA approval of AstraZeneca's Airsupra (albuterol/budesonide) the first and only rescue medication to reduce risk of asthma exacerbations in adults.
Ticker: AZN
Executed On: Jan 26, 2023 at 02:00 PM EST
A second look: Discussing the recent data presented at SABSC on AstraZeneca's capivasertib in combination with FASLODEX (fulvestrant).
Ticker: AZN
Executed On: Jan 10, 2023 at 12:00 PM EST
Discussing the recent data presented at SABSC on AstraZeneca's capivasertib in combination with FASLODEX (fulvestrant) in locally advanced or metastatic breast cancer
Ticker: AZN
Executed On: Jan 04, 2023 at 02:00 PM EST
A third look at the results from the HIMALAYA P3 trial of Imjudo(tremelimumab) in combination with Imfinzi and the novel STRIDE regimen in patients with unresectable hepatocellular carcinoma
Ticker: AZN
Executed On: Dec 05, 2022 at 03:00 PM EST
Reviewing the potential of Astra Zeneca's PT027, an inhaler combining a short-acting beta2-agonist (SABA) and inhaled corticosteroid (ICS) as a rescue treatment for asthma.
Ticker: AZN
Executed On: Dec 05, 2022 at 12:00 PM EST
A second look at the results from the HIMALAYA P3 trial of Imjudo(tremelimumab) in combination with Imfinzi and the novel STRIDE regimen in patients with unresectable hepatocellular carcinoma
Ticker: AZN
Executed On: Nov 30, 2022 at 06:00 PM EST
A look at the results from the HIMALAYA P3 trial of Imjudo(tremelimumab) in combination with Imfinzi and the novel STRIDE regimen in patients with unresectable hepatocellular carcinoma
Ticker: AZN
Executed On: Nov 22, 2022 at 07:30 PM EST
A Third Look: Examining the current use of Dapagliflozin (Farxiga) in the heart failure treatment landscape
Ticker: AZN
Executed On: Nov 21, 2022 at 04:30 PM EST
A Second Look: Examining the current use of Dapagliflozin (Farxiga) in the heart failure treatment landscape
Tickers: AZN, LLY
Executed On: Nov 21, 2022 at 01:00 PM EST
A discussion about the standard of care for Neuromyelitis Optica Spectrum Disorder and the potential of AstraZeneca's Ultomiris.
Ticker: AZN
Executed On: Nov 10, 2022 at 04:00 PM EST
Discussing the current treatment landscape for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and the potential of Zanubrutinib(BRUKINSA®) and the phase 3 ALPINE trial.
Tickers: BGNE, AZN, ABBV
Executed On: Nov 04, 2022 at 09:15 AM EDT
Examining the current use of Dapagliflozin (Farxiga) in the heart failure treatment landscape
Tickers: AZN, LLY
Executed On: Nov 03, 2022 at 12:00 PM EDT
A Second View: Understanding the Landscape of Type-2 Diabetes Treatments and the prevalence of Lilly's Mounjaro.
Tickers: LLY, NVO, AZN
Executed On: Oct 20, 2022 at 09:30 AM EDT
A third look at the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022
Tickers: GILD, AZN, DSNKY
Executed On: Oct 06, 2022 at 04:00 PM EDT
A third look into the clinical landscape for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Also reviewing the recent data from Alexion's oral factor D inhibitor, Danicopan, an add on to Ultomiris or Soliris
Tickers: AZN, ALXN
Executed On: Oct 04, 2022 at 11:00 AM EDT
Discussing the P2 acelERA BC study of Giredestrant in patients with ER+, HER2– locally advanced/metastatic breast cancer and the AMEERA-3 Phase 2 study of amcenestrant in patients with endocrine-resistant ER+/HER2− advanced breast cancer
Tickers: SNY, RHHBY, GILD, AZN, DSKYN
Executed On: Oct 04, 2022 at 10:00 AM EDT
A second look at the P1 data presented at ESMO for ubamatamab, a CD3-targeting bispecific antibody under investigation for recurrent ovarian cancer
Tickers: REGN, AZN, CLVS, IMGN, GSK, RHHBY
Executed On: Sep 29, 2022 at 05:15 PM EDT
A second look at the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022
Tickers: GILD, AZN, DSNKY
Executed On: Sep 28, 2022 at 05:00 PM EDT
A second look into the clinical landscape for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Also reviewing the recent data from Alexion's oral factor D inhibitor, Danicopan, an add on to Ultomiris or Soliris
Tickers: AZN, ALXN
Executed On: Sep 26, 2022 at 04:00 PM EDT
A look at the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022
Tickers: GILD, AZN, DSNKY
Executed On: Sep 23, 2022 at 09:00 AM EDT
A look into the clinical landscape for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Also reviewing the recent data from Alexion's oral factor D inhibitor, Danicopan, an add on to Ultomiris or Soliris
Tickers: AZN, APLS
Executed On: Sep 20, 2022 at 06:00 PM EDT
A look at the data presented at the ESMO 2022 Conference for the CXCR2 antagonist, AZD5069, in combination with enzalutamide for patients with metastatic castration resistant prostate cancer(mCRPC)
Tickers: AZN, PFE
Executed On: Sep 16, 2022 at 04:00 PM EDT
Discussing the safety and efficacy of the new covid vaccines targeting omicron variant
Tickers: MRNA, AZN, PFE
Executed On: Sep 09, 2022 at 05:30 PM EDT
A look at the NSCLC treatment landscape with special attention to Tabrecta(capmatinib) in NSCLC with MET exon-14 skipping mutations.
Tickers: INCY, REGN, BMY, RHHBY, AZN
Executed On: Aug 18, 2022 at 11:00 AM EDT
A second look at Idorsia's phase III trials results for its resistant hypertension drug, Aprocitentan
Tickers: IDRSF, CINC, AZN, KBP Biosciences
Executed On: Jul 06, 2022 at 01:30 PM EDT
Discussing the potential use of Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients with HER2 mBC
Ticker: AZN
Executed On: Jun 27, 2022 at 06:00 PM EDT
Discussing Tezspire (tezepelumab) in severe asthma as an add-on maintenance therapy for severe uncontrolled asthma. 4th look
Tickers: AMGN, AZN
Executed On: Mar 23, 2022 at 02:45 PM EDT
Discussing Tezspire (tezepelumab) in severe asthma as an add-on maintenance therapy for severe uncontrolled asthma. 3rd look
Tickers: AMGN, AZN
Executed On: Mar 16, 2022 at 12:30 PM EDT
Discussing Tezspire (tezepelumab) in severe asthma as an add-on maintenance therapy for severe uncontrolled asthma. 2nd look
Tickers: AMGN, AZN
Executed On: Mar 03, 2022 at 01:00 PM EST
Discussing Tezspire (tezepelumab) in severe asthma as an add-on maintenance therapy for severe uncontrolled asthma. 1st look
Tickers: AMGN, AZN
Executed On: Feb 23, 2022 at 04:00 PM EST

Upcoming & Overdue Catalysts (AZN)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (AZN)

Don’t see a strategic initiative related to the company you care about? Create your own!